IDH2 and neoplasm: Taking advantage of the natural features of cancer cells that affect determinant metabolic pathways and profiles such as IDH mutations and glutamine-glutamate metabolism can be a valuable opportunity to find effective new strategies that trigger a bottom-up cancer cell death and tumor impairment by targeting the most basal life-sustaining mechanisms and reflecting their disturbance in tumor regression.